News

NEWS

PPF Group expands in the field of biotechnology and immunotherapy

PPF Group has acquired a minority stake in OriBase Pharma, a biotechnology company which specialises in the development of new therapies in oncology. The acquisition will strengthen PPF’s research and product portfolio, currently represented by SOTIO which is developing a next-generation Active Cellular Immunotherapy based on activated dendritic cells for the treatment of cancer and autoimmune diseases. Cooperation between OriBase Pharma and SOTIO will enable the effective sharing of research, expertise and clinical development capacities in the area of immunotherapy and targeted therapies.

NEWS

SOTIO Receives VHP approval to start Phase III Clinical Trial

SOTIO a.s., Prague, announced today that it received from the EU Heads of Medicines Agencies (HMA) a positive decision on a substantial amendment to its Phase III VIABLE Clinical Trial of DCVAC/PCa – an active cellular immunotherapy for the treatment of prostate cancer. The HMA originally approved SOTIO’s submission for the VIABLE Phase III clinical trial in March 2013. This amendment was submitted by SOTIO as part of the European Voluntary Harmonisation Procedure (VHP), based on feedback received from US Food and Drug Administration (FDA). Amendment was developed to ensure unification of the protocol design for EU and US. SOTIO plans to start recruiting patients in the trial beginning in March 2014. 

NEWS

Ladislav Bartoníček to become new SOTIO Chief Executive Officer

A new Chief Executive Officer of SOTIO, a biotechnology company belonging to the PPF Group, will become from 1st March 2014 one of the PPF shareholders, Ladislav Bartoníček (49). He will replace in the office Karel Nohejl (44) who will continue working at the PPF Group in other positions.